HK79791A - Solid galenical forms for oral application containing 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin, and process for their preparation - Google Patents

Solid galenical forms for oral application containing 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin, and process for their preparation Download PDF

Info

Publication number
HK79791A
HK79791A HK797/91A HK79791A HK79791A HK 79791 A HK79791 A HK 79791A HK 797/91 A HK797/91 A HK 797/91A HK 79791 A HK79791 A HK 79791A HK 79791 A HK79791 A HK 79791A
Authority
HK
Hong Kong
Prior art keywords
active substance
solid pharmaceutical
pharmaceutical preparations
oral administration
basic excipient
Prior art date
Application number
HK797/91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Alain Etienne
Peter Dr. Dipl.-Chem. Gruber
Ulrich Dr. Dipl.-Chem. Busch
Original Assignee
Dr. Karl Thomae Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Karl Thomae Gmbh filed Critical Dr. Karl Thomae Gmbh
Publication of HK79791A publication Critical patent/HK79791A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK797/91A 1985-07-10 1991-10-10 Solid galenical forms for oral application containing 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin, and process for their preparation HK79791A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853524572 DE3524572A1 (de) 1985-07-10 1985-07-10 Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
HK79791A true HK79791A (en) 1991-10-18

Family

ID=6275375

Family Applications (1)

Application Number Title Priority Date Filing Date
HK797/91A HK79791A (en) 1985-07-10 1991-10-10 Solid galenical forms for oral application containing 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin, and process for their preparation

Country Status (25)

Country Link
US (1) US4755385A (da)
EP (1) EP0208971B1 (da)
JP (1) JPH0688905B2 (da)
KR (1) KR930010586B1 (da)
AT (1) ATE63819T1 (da)
AU (1) AU586262B2 (da)
CA (1) CA1271138A (da)
DD (1) DD248057A5 (da)
DE (2) DE3524572A1 (da)
DK (1) DK165670C (da)
ES (1) ES2000269A6 (da)
FI (1) FI85649C (da)
GR (1) GR861762B (da)
HK (1) HK79791A (da)
HU (1) HU195730B (da)
IE (1) IE58951B1 (da)
IL (1) IL79375A (da)
MX (1) MX9202785A (da)
NL (1) NL970004I2 (da)
NO (1) NO175351C (da)
NZ (1) NZ216794A (da)
PH (1) PH26147A (da)
PT (1) PT82949B (da)
SG (1) SG72191G (da)
ZA (1) ZA865105B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
CA2182282C (en) * 1994-02-16 2006-04-18 Jacqueline E. Briskin Process for preparing fine particle pharmaceutical formulations
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US6495180B1 (en) 1995-12-22 2002-12-17 Tamer International, Ltd. Acid reduced whole bean coffee and process
US6045843A (en) * 1995-12-22 2000-04-04 Tamer International, Inc. Acid-reduced, whole bean coffee process
US6066342A (en) * 1995-12-22 2000-05-23 Tamer International, Ltd. Antacid composition
US5853787A (en) * 1995-12-22 1998-12-29 Tamer International Method for reducing coffee acidity
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US20020018754A1 (en) * 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
US6096328A (en) 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
JP4980527B2 (ja) * 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
EP1196137B1 (en) 1999-07-02 2004-12-22 The Procter & Gamble Company Systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
KR100640701B1 (ko) * 2000-06-28 2006-10-31 더 프록터 앤드 갬블 캄파니 과산화물 활성제의 안정성을 증가시키는 구조물 및 조성물
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US6949240B2 (en) * 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
CA2602392A1 (en) 2005-03-22 2006-09-28 Losan Pharma Gmbh Solubilized ibuprofen
DK1916995T4 (da) * 2005-07-29 2022-10-03 Stichting Groningen Centre For Drug Res Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
JPWO2007126039A1 (ja) * 2006-04-28 2009-09-10 塩野義製薬株式会社 マクロライド系抗生物質の被覆製剤
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
MX361101B (es) 2012-10-17 2018-11-27 Procter & Gamble Tira para el suministro de un activo para el cuidado bucal y métodos para aplicar activos para el cuidado bucal.
GB2533593A (en) * 2014-12-22 2016-06-29 Parkside Flexibles (Europe) Ltd Package

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
AT342770B (de) * 1975-04-07 1978-04-25 Thomae Gmbh Dr K Verfahren zur herstellung neuer erythromycinderivate
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法

Also Published As

Publication number Publication date
KR930010586B1 (ko) 1993-10-30
FI862898A0 (fi) 1986-07-10
AU586262B2 (en) 1989-07-06
DE3679463D1 (de) 1991-07-04
KR870000920A (ko) 1987-03-10
NO175351B (no) 1994-06-27
DK324786D0 (da) 1986-07-08
DK324786A (da) 1987-01-11
DE3524572A1 (de) 1987-01-15
ZA865105B (en) 1988-03-30
HU195730B (en) 1988-07-28
JPH0688905B2 (ja) 1994-11-09
US4755385A (en) 1988-07-05
MX9202785A (es) 1992-06-30
EP0208971A2 (de) 1987-01-21
PH26147A (en) 1992-03-18
HUT42945A (en) 1987-09-28
ATE63819T1 (de) 1991-06-15
NZ216794A (en) 1988-11-29
DK165670C (da) 1993-06-07
EP0208971A3 (en) 1988-01-27
CA1271138A (en) 1990-07-03
EP0208971B1 (de) 1991-05-29
NO175351C (no) 1994-10-05
JPS6212717A (ja) 1987-01-21
DD248057A5 (de) 1987-07-29
GR861762B (en) 1986-11-10
ES2000269A6 (es) 1988-02-01
DK165670B (da) 1993-01-04
IL79375A (en) 1990-01-18
NL970004I1 (nl) 1997-04-01
PT82949A (de) 1986-08-01
FI85649C (fi) 1992-05-25
SG72191G (en) 1991-11-22
NO862772L (no) 1987-01-12
NO862772D0 (no) 1986-07-09
AU5987686A (en) 1987-01-15
NL970004I2 (nl) 1997-06-02
FI862898A7 (fi) 1987-01-11
IL79375A0 (en) 1986-10-31
IE861842L (en) 1987-01-10
PT82949B (pt) 1989-01-30
IE58951B1 (en) 1993-12-01
FI85649B (fi) 1992-02-14

Similar Documents

Publication Publication Date Title
US4755385A (en) Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin
DE69832731T2 (de) Arzneimittel mit magensaftresistentem überzug und methode zur herstellung
EP1562573B1 (en) Pharmaceutical pellets comprising tamsulosin and a process for making the same
EP0523847B1 (en) Taste mask coating for preparation of chewable pharmaceutical tablets
AU764280B2 (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
WO2012072570A2 (de) Verfahren zur herstellung einer ppi-haltigen pharmazeutischen zubereitung
JPH0122245B2 (da)
BG65443B1 (bg) Ентерично покрит фармацевтичен състав, съдържащ диданозин
IE67062B1 (en) Taste masking and sustained release coatings for pharmaceuticals
CZ699A3 (cs) Granulát pro přípravu rychle se rozvolňujících a rychle rozpustných kompozic s vysokým obsahem léčiva
AU604170B2 (en) Chewable medicament tablet containing means for taste masking
EP0625353B1 (en) Slow-release pharmaceutical composition containing a bile acid as an active ingredient
HU228856B1 (en) Modified release oral pharmaceutical composition containing 5-asa for the treatment of bowel diseases
AU633757B2 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
JPH03500288A (ja) 徐放性ニフェジピン製剤
RU2140272C1 (ru) Способ получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия (варианты), таблетки и гранулят для получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия
DE29824797U1 (de) Magensaftresistent überzogene Arzneimittel
KR100274698B1 (ko) 다층 알칼리 코팅에 의한 오메프라졸의 경구제제 및 그 제조방법
JPS61221116A (ja) 錠剤の組成物
TR2022002174A2 (tr) Tolvaptan i̇çeren kati bi̇r farmasöti̇k kompozi̇syon
EP1119348A2 (en) Enteric coated pharmaceutical formulation
JPS5967222A (ja) 持続性セフアトリジン製剤
MXPA00010963A (en) Enteric coated pharmaceutical composition and method of manufacturing

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060626